CoDa Therapeutics, Inc.
CoDa Therapeutics is a biopharmaceutical company focused on the development and commercialization of a new generation of wound care therapeutics known as “gap junction modulators.”
The company’s Gap Junction Modulation technology targets the cell-to-cell communication that leads, amongst other things, to cell death in the initial phases of wound-healing following an injury.
Square 1 Announces $6 Million Credit Facility to CoDa Therapeutics, Inc.
SAN DIEGO, California - October 6, 2011
Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan...
CoDa Therapeutics Appoints Chief Medical Officer
San Diego, California – May 2, 2011
CoDa Therapeutics, Inc. announced today that it has
named David E. Eisenbud, MD, as CMO (Chief Medical Officer). The appointment of Dr. Eisenbud is key to...
CoDa Therapeutics Closes $19 Million Series B Financing Round
San Diego, California - April 18, 2011
CoDa Therapeutics, Inc. announced today that it has
raised $19.2 million in a Series B financing. Current investors Domain Associates, GBS Venture
Partners...
CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON® in Chronic Venous Leg Ulcers
San Diego, California, May 25, 2010 – CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today...